# Semaglutide

## Ozempic inj 4mg/3mL

| TAH Drug Code      | [IOZE4](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOZE4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Type 2 diabetes mellitus. Prophylaxis of disorder of cardiovascular system with type 2 diabetes mellitus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dosing             | SC, 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly; may increase to maximum 1 mg once weekly if additional glycemic control is needed after at least 4 weeks of the 0.5 mg weekly dosage.                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Hypoglycemia (Monotherapy, 1.6-3.8%; combination therapy, 6-30%), Abdominal pain (Diabetes, 5.7-11%; weight management, 15-20%), Constipation (Diabetes, 3.1-6%; weight management, 6-24%), Diarrhea (Diabetes, 8.5-10%; weight management, 22-30%), Nausea (Diabetes, 11-20.3%; weight management, 42-44%), Vomiting (Diabetes, 5-9.2% ; weight management, 24-36%), Headache (14-17%) Serious: Increased heart rate, Medullary thyroid carcinoma, Cholecystitis (0.6-0.8%), Cholelithiasis (0.4-3.8%), Pancreatitis, Anaphylaxis, Hypersensitivity reaction, Retinopathy due to diabetes mellitus, Anxiety, Depression, Suicidal thoughts, Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/semaglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

## Wegovy 1mg pre-filled pen (4mg/3mL)

| TAH Drug Code      | [IWEG1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IWEG1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:-------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Weight management, chronic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Dosing             | Initiate and adjust dose using the following schedule: In patients who do not tolerate a dosage increase, consider delaying the increase for an additional 4 weeks: Week 1 through week 4: 0.25 mg once weekly. Week 5 through week 8: 0.5 mg once weekly. Week 9 through week 12: 1 mg once weekly. Week 13 through week 16: 1.7 mg once weekly. Week 17 and thereafter (maintenance dosage): 2.4 mg once weekly (preferred regimen); if not tolerated, may use an alternative maintenance dosage of 1.7 mg once weekly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Hypersensitivity to semaglutide or any component of the formulation; personal or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | >10%: Gastrointestinal: Abdominal pain (adolescents, adults: 6% to 20%), constipation (oral: 5% to 6%; SUBQ: adolescents: 6%; adults: 3% to 24%), diarrhea (oral: 9% to 10%; SUBQ: adolescents, adults: 9% to 30%), nausea (oral: 11% to 20%; SUBQ: adolescents, adults: 16% to 44%), vomiting (oral: 6% to 8%; SUBQ: adolescents: 36%, adults: 5% to 24%) Nervous system: Fatigue (SUBQ: 11%), headache (SUBQ: adolescents, adults: 14% to 17%) Respiratory: Nasopharyngitis (SUBQ: adolescents: 12%) 1% to 10%: Cardiovascular: Hypotension (SUBQ: adolescents, adults: 1% to 2%; including orthostatic hypotension) Dermatologic: Alopecia (SUBQ: adolescents, adults: 3% to 4%), skin rash (SUBQ: adolescents: 3%), urticaria (SUBQ: adolescents: 3%) Endocrine & metabolic: Diabetic retinopathy (complications: 3% to 7%; vitreous hemorrhage: 1%; blindness: <1%), hypoglycemia (SUBQ: 2% to 6%), severe hypoglycemia (<=1%) Gastrointestinal: Abdominal distention (2% to 7%), cholelithiasis (adolescents, adults: 0% to 4%), decreased appetite (oral: 6% to 9%), dysgeusia (SUBQ: <=2%), dyspepsia (oral: 0.6% to 3%; SUBQ: 3% to 9%), eructation (adolescents, adults: <=7%), flatulence (1% to 6%), gastritis (2% to 4%), gastroenteritis (SUBQ: adolescents, adults: 6% to 7%), gastroesophageal reflux disease (adolescents, adults: 2% to 5%), viral gastroenteritis (SUBQ: 4%) Genitourinary: Urinary tract infection (SUBQ: adolescents: 4%), urolithiasis (SUBQ: 1%) Hepatic: Increased serum alanine aminotransferase (SUBQ: adolescents: 3%) Immunologic: Antibody development (<=3%) Infection: Influenza (SUBQ: adolescents: 3%) Nervous system: Anxiety (SUBQ: adolescents: 4%), dizziness (SUBQ: adolescents, adults: 8%), dysesthesia (SUBQ: 2%; including allodynia, burning sensation, hyperesthesia, paresthesia) Neuromuscular & skeletal: Bone fracture (SUBQ: 1% to 2%), sprain (ligament: SUBQ: adolescents: 4%) Respiratory: Sinusitis (SUBQ: adolescents: 4%) <1%: Gastrointestinal: Acute pancreatitis (including hemorrhagic pancreatitis, necrotizing pancreatitis), cholecystitis (SUBQ: adolescents, adults) Local: Discomfort at injection site (SUBQ), erythema at injection site (SUBQ) Frequency not defined: Gastrointestinal: Hemorrhoids (SUBQ), hiccups (SUBQ), increased serum amylase (adolescents, adults: mean increase from baseline of 10% to 16%), increased serum lipase (adolescents, adults: mean increase from baseline of 22% to 39%) Postmarketing (any formulation or population): Cardiovascular: Increased heart rate Dermatologic: Bullous pemphigoid Gastrointestinal: Biliary tract disease, cholecystectomy, delayed gastric emptying, gallbladder disease, intestinal obstruction, xerostomia Hepatic: Hepatic injury (increased serum alkaline phosphatase, jaundice, biliary cirrhosis) Hypersensitivity: Anaphylaxis, angioedema Nervous system: Dysesthesia Neuromuscular & skeletal: Lupus erythematosus Renal: Acute interstitial nephritis, acute kidney injury |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| More Info          | [UpToDate](https://www.uptodate.com/contents/semaglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

## Rybelsus 7mg

| TAH Drug Code      | [ORYB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORYB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; can be used as monotherapy if patient is intolerant or contraindicated to metformin or be used in combination with other diabetes medications.                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | 3 mg orally QD for 30 days, then increase dose to 7 mg QD. Dose may be increased to 14 mg QD if additional glycemic control is needed after at least 30 days receiving 7-mg dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | [Common] Hypoglycemia (Monotherapy, 1.6-3.8%; combination therapy, 6-30% ), Abdominal pain (Diabetes, 5.7-11% ; weight management, 15-20% ), Constipation (Diabetes, 3.1-6% ; weight management, 6-24% ), Diarrhea (Diabetes, 8.5-10% ; weight management, 22-30% ), Nausea (Diabetes, 11-20.3% ; weight management, 42-44% ), Vomiting (Diabetes, 5-9.2% ; weight management, 24-36% ), Headache (14-17% ) [Serious] Increased heart rate, Medullary thyroid carcinoma, Cholecystitis (0.6-0.8% ), Cholelithiasis (0.4-3.8% ), Pancreatitis, Anaphylaxis, Hypersensitivity reaction, Retinopathy due to diabetes mellitus, Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/semaglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

## RYBELSUS 14mg

| TAH Drug Code      | [ORYB14](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORYB14)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; can be used as monotherapy if patient is intolerant or contraindicated to metformin or be used in combination with other diabetes medications.                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | 3 mg orally QD for 30 days, then increase dose to 7 mg QD. Dose may be increased to 14 mg QD if additional glycemic control is needed after at least 30 days receiving 7-mg dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Adverse Effects    | [Common] Hypoglycemia (Monotherapy, 1.6-3.8%; combination therapy, 6-30% ), Abdominal pain (Diabetes, 5.7-11% ; weight management, 15-20% ), Constipation (Diabetes, 3.1-6% ; weight management, 6-24% ), Diarrhea (Diabetes, 8.5-10% ; weight management, 22-30% ), Nausea (Diabetes, 11-20.3% ; weight management, 42-44% ), Vomiting (Diabetes, 5-9.2% ; weight management, 24-36% ), Headache (14-17% ) [Serious] Increased heart rate, Medullary thyroid carcinoma, Cholecystitis (0.6-0.8% ), Cholelithiasis (0.4-3.8% ), Pancreatitis, Anaphylaxis, Hypersensitivity reaction, Retinopathy due to diabetes mellitus, Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| More Info          | [UpToDate](https://www.uptodate.com/contents/semaglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

